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drug therapy use in a practice setting in patients who did or didn’t receive the 
assay. Methods: Patients with initial visits for ER+, HER2- ESBC to the Regional 
Cancer Care Associates physician practice in 2009-2013 were identified using COTA, 
an oncology outcomes and cost tracking database. A case-control design was used to 
describe demographic, clinical, adjuvant CT, and supportive care therapy informa-
tion for patients < 70 years. Results: 158 Case patients who received the assay 
and 111 Controls who did not were identified. Cases were older, had larger tumors, 
and had more stage 1 tumors (p < 0.05). A significantly lower proportion in the 
Case group (21%) received CT compared to the Control group (56%; p< 0.001). The 
proportions of N- Case patients who received CT were 2%, 33%, and 100% in the 
Low, Intermediate and High Recurrence Score groups, respectively. Fifty of the 269 
patients (10 Cases, 40 Controls) were N+. In N+ Cases (n = 10), no Low risk group 
patients (n= 6) received CT, while all Intermediate and High risk group patients 
did. The proportion of Case patients who received pegfilgrastim or aprepitant was 
significantly lower than in the Control group (p< 0.001). The proportions of N+ Case 
patients receiving pegfilgrastim or aprepitant were also lower than in the N+ Control 
group. ConClusions: Physicians appear to be selective in using the 21-Gene assay 
in ESBC patients. Tested patients were less likely to receive CT and other supportive 
therapies. A majority of N+ patients tested had low Recurrence Score results and 
avoided CT, supporting potential utility of the assay in these patients.
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objeCtives: Assess the trends in Human Epidermal Growth Factor Receptor 2 
(HER2), Epidermal Growth Factor Receptor mutation (EGFRm) and KRAS biomarker 
testing in BC, mNSCLC and mCRC respectively in EU. Methods: A multi-country 
retrospective medical chart-review of BC/mNSCLC/mCRC patients were conducted 
by cancer treating physicians in Germany/France/Spain/Italy (4EU) and the UK; 
Data collection period was BC:2004-2013, mNSCLC/mCRC:2009-2014. Physicians 
were recruited from a geographically representative sample in each country. 
Approximately 10-25 eligible patients in respective tumor types on usual care 
anti-cancer regimen were identified by each physician within each of the four-
quarterly study observation-windows in respective years. Physicians abstracted 
data on patient demographics, disease status, treatment patterns and biomarker 
status .The analysis focused on HER2, EGFRm and KRAS testing trends. Results: 
An average of 7500 BC (4EU~6000; UK~1500), 3600 mNSCLC (4EU~3000; UK~600) and 
750 mCRC (4EU~600; UK~150) patient charts were abstracted per year. Percentage BC 
patients tested for HER2 increased in 4EU from 2004(70%) to 2009(89%) to 2013(97%), 
while the testing rates started relatively low in the UK initially (2004:23%; 2009:81%) 
and reached 4EU levels in 2013 (98%). EGFRm testing rates in mNSCLC increased 
in 4EU from December-2009(7%) to December-2011(53%) to December-2013(62%), 
and the UK testing rates increased during the corresponding period to be on-par 
despite starting slow (December-2009:2%; December-2011:33%; December-2013:62%). 
KRAS mutation testing rates in mCRC showed the largest difference between 
4EU (December-2009:61%; December-2011:89%; December-2013:92%) and UK 
(December-2009:6%; December-2011:26%; December-2013:62%) throughout the 
evaluation period. ConClusions: HER2/EGFRm/KRAS biomarker testing rates 
initially lagged behind in the UK in comparison to Germany/France/Italy/Spain, 
and the difference existed throughout the study evaluation period for KRAS, while 
HER2/EGFRm testing rates converged in 2013. Factors influencing these observed 
patterns (incl. access to medicines with relevant indications) needs further scru-
tiny to facilitate optimal care delivery utilizing targeted oncology therapeutics to 
benefit patients.
PMD68
The rise of The value analysis coMMiTTee aT us hosPiTals, beTTer or 
worse for MeDical Device coMPanies?
Hristova-Neeley D.1, Armstrong S.1, Garfield S.1, Ertel D.2
1GfK Custom Research, Wayland, MA, USA, 2Einstein Healthcare Network, Philadelphia, PA, USA
objeCtives: In response to increased pressure to contain costs and optimize 
patient outcomes, hospitals have implemented standardized decision-making 
processes utilizing value analysis committees (VACs). In 2012, 64% of hospitals 
reported using some form of VAC. The objective of this analysis was to quantify 
the adoption of VAC, the product features considered impactful by VAC, timing 
of review and evidence requirements. Methods: Qualitative interviews (n= 40) 
and quantitative online survey (n= 76) were conducted with C-suite executives, 
purchasers, and clinician leads in the second half of 2014. Research participants 
were drawn from across the US, from a diverse selection of hospitals, including 
large/small, rural/urban and profit/non-profit. Outcomes of the research included 
adoption of VAC, triggers for VAC review, timing of review process, evidence 
requirements and implications for medical device companies. Results: 100% 
of hospitals surveyed report use of VAC for all new products being considered. 
Existing products may undergo a VAC when price or features change. Most prod-
ucts are brought to the VAC by the service line head, although one third of hospitals 
reported use of an automated system. Price of the product was identified as the 
most important consideration during VAC, though patient experience and other 
elements addressed by value-based purchasing were also mentioned. Clinical trial 
data was cited as most influential. However, most hospitals consider products in 
terms of their patient populations and specific context, making clinical trial data 
not optimally relevant to all hospitals. ConClusions: Because VACs are now a 
standard process at US hospitals, medical device companies must have a thorough 
understanding of the process and evidence requirements. Opportunities exist 
for increased communication between innovators and hospital decision-makers 
to align solutions with needs.Facility specific value propositions and data are 
frequently required to secure product approval.
in small populations but were not yet ready to make formal coverage decisions or 
support widespread adoption of specific technologies. Most payers were optimis-
tic about the promise of digital health solutions, with the greatest expectations 
for chronic disease management. Skepticism about incremental value and costs 
led most respondents to desire stringent evaluation criteria and evidence stand-
ards, with standard benchmarks of value preferred. Most expected digital health 
solutions would need to demonstrate decreased costs and improved clinical out-
comes. The most commonly desired attributes of digital health technologies are 
randomized clinical trial results, proven patient compliance, and EHR/EMR integra-
tion. ConClusions: Developing standardized evaluation criteria for digital health 
technologies will drive more consistent coverage outcomes and facilitate faster 
patient access to novel digital health technologies.
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objeCtives: Companion devices enable Mobile Health (mHealth) via remote moni-
toring of patients’ biometrics. By 2020, the global mHealth market is estimated to 
reach $6.28 billion. While mHealth is expected to revolutionize delivery of patient 
care, especially for chronic diseases such as diabetes or asthma, it has not realized 
its full potential. To that end, the objectives of this study were to: 1) Characterize 
benefits that companion devices may deliver to key stakeholders, including patients, 
Health Care Professionals (HCPs), payers, and drug manufacturers; 2) Determine how 
HCPs currently utilize companion devices and key unmet needs; 3) Identify perceived 
roadblocks by payers in coverage & reimbursement of companion devices. Methods: 
Health Technology Assessments (HTAs) and guidelines published between 2010 and 
2014, and publications archived in MEDLINE and PubMed were analyzed to assess 
potential benefits, challenges, and historical valuation of companion devices. 
Additionally, approved companion devices were evaluated to assess their coverage 
and reimbursement and associated evidence requirements in the US and 5 major 
EU markets. Results: Companion devices can potentially deliver benefits across 
the continuum of care that may be categorized into three areas: patient manage-
ment (adherence and compliance), disease management (clinic visits and trend 
alerts), drug management (dosage and clinical events). Current barriers to adoption 
appear to be primarily cost of technology, potentially increased liability exposure, 
compliance with patient confidentiality, challenge in demonstrating positive budget 
impact, and importantly, lack of optimal reimbursement (separate vs bundled pay-
ment). ConClusions: While relatively nascent, companion devices are expected to 
play a role along the full continuum of patient care: from prevention, diagnosis, treat-
ment, to monitoring. As such, this study indicated that the integration of companion 
devices with care plans is potentially hinged around three key issues: a) patient edu-
cation and awareness, b) physician engagement via streamlined clinical workflow, 
and c) demonstration of long-term economic benefits to payers.
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objeCtives: Pregnancy poses a high risk of thyroid dysfunction (TD) causing 
adverse outcomes in mother, fetus and neonate. This makes screening pregnant 
women for TD essential. Universal screening (US) aims to screen all women in 
contrast to targeted screening (TS) where only women at high-risk get tested for TD 
during pregnancy. Existing guidelines do not recommend US. Thus we performed 
meta-analysis to clarify this moot question whether US should be recommended 
for screening TD in pregnancy. Methods: All original research articles compar-
ing the two approaches to detect TD in pregnancy were searched from databases 
PubMed, EBSCO and Cochrane library. Effect estimate is reported as loss ratio (LR) 
signifying missed cases. Missed cases are women considered as low risk during TS. 
Subgroup analysis was done for hyperthyroid and overall thyroid disorder. Further 
sensitivity and specificity analysis was also done. Data is analyzed using CMA 
2.0. Results: Total of 9 studies including 10,888 women was included in present 
analysis. As significant heterogeneity was found between studies (P ‹ 0.001, I2 = 
0.99), random-effects model was used. 46% hypothyroid cases were missed if TS 
was performed instead of US (RR 0.46 (95% CI (0.35 to 0.61), P ≤ 0.001). Sensitivity 
analyses showed (RR 0.40 (95% CI (0.27 to 0 0.55), P≤ 0.001) Specificity test has 
confirmed it (RR 0.31 (95% CI (0.20 to 0.47), P≤ 0.001). Similar trends were seen in 
hyperthyroid (RR 0.56 (95% CI (0.51 to 0.65), P≤ 0.001) and over-all TD (RR 0.49 (95% 
CI (0.43 to 0.60), P≤ 0.001). ConClusions: Almost half of the cases were missed 
on TS. The present pooled analysis recommends US to identify overall TD as well 
as hypothyroid cases in pregnancy. This serves as a strong evidence for inclusion 
of US into guidelines.
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objeCtives: Patients with low risk 21-Gene Breast Cancer Assay results can safely 
avoid chemotherapy (CT), as has been shown in protocol-driven studies. This study’s 
objective was to compare, using practice management data, CT and supportive 
